Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2017

Open Access 01-12-2017 | Review

Tumor-related interleukins: old validated targets for new anti-cancer drug development

Authors: Sarra Setrerrahmane, Hanmei Xu

Published in: Molecular Cancer | Issue 1/2017

Login to get access

Abstract

In-depth knowledge of cancer molecular and cellular mechanisms have revealed a strong regulation of cancer development and progression by the inflammation which orchestrates the tumor microenvironment. Immune cells, residents or recruited, in the inflammation milieu can have rather contrasting effects during cancer development. Accumulated clinical and experimental data support the notion that acute inflammation could exert an immunoprotective effect leading to tumor eradication. However, chronic immune response promotes tumor growth and invasion. These reactions are mediated by soluble mediators or cytokines produced by either host immune cells or tumor cells themselves. Herein, we provide an overview of the current understanding of the role of the best-validated cytokines involved in tumor progression, IL-1, IL-4 and IL-6; in addition to IL-2 cytokines family, which is known to promote tumor eradication by immune cells. Furthermore, we summarize the clinical attempts to block or bolster the effect of these tumor-related interleukins in anti-cancer therapy development.
Literature
1.
2.
3.
Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002;16:217.PubMed
4.
Visser KED, Coussens ELM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24.PubMedCrossRef
5.
6.
Denardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research. 2007;9:212.PubMedPubMedCentralCrossRef
7.
Elomar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124:1193.CrossRef
8.
Negus RP, Stamp GW, Hadley J, et al. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol. 1997;150:1723–34.PubMedPubMedCentral
9.
Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6:1182.PubMedCrossRef
10.
Mantovani A, Sozzani, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.PubMedCrossRef
11.
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–48.PubMedCrossRef
12.
Pyfferoen L, Brabants E, Everaert C, et al. The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome[J]. OncoImmunology. 2017;6(1):e1253655.
13.
Westergaard MCW, Andersen R, Kjeldsen JW et al. 54PDPreclinical Development of tumor-infiltrating lymphocytes (TILs) based adoptive cell transfer immunotherapy (ACT) for patients with advanced ovarian cancer. 2016.
14.
Denardo D, Coussens L. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. 2007.
15.
Sektioglu IM, Carretero R, Bulbuc N et al. Basophils promote tumor rejection via chemotaxis and infiltration of CD8+ T cells. Cancer Research. 2016;77:291.
16.
Schwartz C, O'Grady K, Lavelle EC et al. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity - emerging roles in obesity, intestinal inflammation and cancer. European Journal of Immunology. 2016;46:1091–1100. 
17.
Benbaruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52.CrossRef
18.
Kim R, Emi M, Tanabe K, et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527.PubMedCrossRef
19.
de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006;13:118–37.PubMedCrossRef
20.
Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113:986–92.PubMedCrossRef
21.
Kumar J, Ward AC. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications. Biochim Biophys Acta. 1845;2014:117–25.
22.
23.
Ishiko T, Mita S, Hidaka H et al. Human carcinoma cells express IL-8 and IL-8 receptor: their role and regulation in cancer biology. International Congress. 2003;1255:327–32.
24.
Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11–20.PubMedCrossRef
25.
26.
Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485.PubMedCrossRef
27.
Lotze MT, Chang AE, Seipp CA, et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA. 1986;256:3117–24.PubMedCrossRef
28.
Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474.PubMedPubMedCentralCrossRef
29.
Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose Interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–32.PubMedPubMedCentralCrossRef
30.
Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–8.PubMedCrossRef
31.
Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25:377.PubMedCrossRef
32.
33.
34.
Kronin V, Vremec D, Shortman K. Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function? Int Immunol. 1998;10:237–40.PubMedCrossRef
35.
Krieg C, Létourneau S, Pantaleo G, et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci. 2010;107:11906–11.PubMedPubMedCentralCrossRef
36.
Siegel JP, Sharon M, Smith PL, et al. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science. 1987;238:75–8.PubMedCrossRef
37.
Bosco MC, Espinoza-Delgado I, Schwabe M, et al. Regulation by interleukin-2 (IL-2) and interferon gamma of IL-2 receptor gamma chain gene expression in human monocytes. Blood. 1994;83:2995–3002.PubMed
38.
Wang HM, Smith KA. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Ex Med. 1987;166:1055.CrossRef
39.
Rickert M, Wang X, Boulanger MJ, et al. The structure of interleukin-2 complexed with its alpha receptor. Science. 2005;308:1477–80.PubMedCrossRef
40.
Takeshita T, Asao H, Ohtani K, et al. Cloning of the gamma chain of the human IL-2 receptor. Science. 1992;257:379–82.PubMedCrossRef
41.
Pipkin ME, Sacks JA, Cruzguilloty F et al. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity. 2010;32:91–103.
42.
Sim GC, Martinorozco N, Jin L, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Investig. 2014;124:99.PubMedCrossRef
43.
44.
Fettelschoss A, Kistowska M, Leibundgut-Landmann S, et al. Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A. 2011;108:18055–60.PubMedPubMedCentralCrossRef
45.
46.
Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228:307.PubMedPubMedCentralCrossRef
47.
Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with Cytotoxic T lymphocyte–associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005–16.PubMedPubMedCentralCrossRef
48.
Baek S, Kim YM, Kim SB, et al. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol. 2015;12:87–95.
49.
Dudley ME, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–4.PubMedPubMedCentralCrossRef
50.
Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-Myeloablative but Lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346.PubMedPubMedCentralCrossRef
51.
Cavalieri S, Cazzaniga S, Geuna M et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood. 2003;102:497–505. 
52.
Langerman A, Callender GG, Nishimura MI. Retroviral transduction of peptide stimulated t cells can generate dual t cell receptor-expressing (bifunctional) t cells reactive with two defined antigens. J Transl Med. 2004;2:42.PubMedPubMedCentralCrossRef
53.
Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123:3750.PubMedPubMedCentralCrossRef
54.
Zhu EF, Gai SA, Opel CF, et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell. 2015;27:489.PubMedPubMedCentralCrossRef
55.
Chaurasiya S, Hew P, Crosley P, et al. Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences. Cancer Gene Ther. 2016;23:178.PubMedCrossRef
56.
Tähtinen S, Blattner C, Vähä-Koskela M et al. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. Journal of Immunotherapy. 2016;39:343.
57.
Weide B, Neri D, Elia G. Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunol Immunother. 2017;66:647–56.PubMedCrossRef
58.
Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 1993;53:2597–602.PubMed
59.
Marzec M, Liu X, Kasprzycka M, et al. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood. 2008;111:2181.PubMedPubMedCentralCrossRef
60.
De TD, Meazza R, Capaia M, et al. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood. 2008;111:517.CrossRef
61.
Ochoa MC, Mazzolini G, Hervas-Stubbs S, et al. Interleukin-15 in gene therapy of cancer. Current Gene Therapy. 2013;13:15.PubMedCrossRef
62.
Cornish GH, Sinclair LV, Cantrell DA. Differential regulation of T-cell growth by IL-2 and IL-15. Blood. 2006;108:600–8.PubMedCrossRef
63.
Evans R, Fuller JA, Christianson G, et al. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell Immunol. 1997;179:66–73.PubMedCrossRef
64.
Yu P, Steel JC, Zhang M et al. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances anti-tumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clinical Cancer Research An Official Journal of the American Association for Cancer Research. 2010;16:6019.
65.
Pfeiffer MM, Schumm M, Müller I, et al. IL-15-stimulated CD3|[sol]|CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT. Leukemia. 2012;26:2435–9.PubMedCrossRef
66.
Rettinger E, Bonig H, Wehner S, et al. Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Transplant. 2013;48:1141–3.PubMedCrossRef
67.
68.
Wang G, Tschoi M, Spolski R, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 2003;63:9016–22.PubMed
69.
Hinrichs CS, Spolski R, Paulos CM, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008;111:5326.PubMedPubMedCentralCrossRef
70.
Res C. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011;71:3516–27.CrossRef
71.
Davis ID, Brady B, Kefford RF, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009;15:2123–9.PubMedCrossRef
72.
Rider P, Carmi Y, Guttman O, et al. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187:4835.PubMedCrossRef
73.
Nakae S, Saijo S, Horai R, et al. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci. 2003;100:5986.PubMedPubMedCentralCrossRef
74.
Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J of Clin invest. 2001;107:135–142.
75.
Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Chin J Lung Cancer. 2009;8:3267–73.
76.
Jin L, Yuan RQ, Fuchs A, et al. Expression of interleukin-1beta in human breast carcinoma. Cancer. 1997;80:421–34.PubMedCrossRef
77.
Miller LJ, Kurtzman SH, Anderson K, et al. Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist. Cancer Investig. 2000;18:293–302.CrossRef
78.
Wetzler M, Kurzrock R, Estrov Z, et al. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994;84:3142.PubMed
79.
Mitsunaga S, Ikeda M, Shimizu S, et al. Serum levels of IL-6 and IL-1|[beta]| can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 2013;108:2063–9.PubMedPubMedCentralCrossRef
80.
Elaraj DM, Weinreich DM, Varghese S, et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res. 2006;12:1088–96.PubMedCrossRef
81.
Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222:222–41.PubMedCrossRef
82.
Chen X, Lv Q, Hong Y, et al. IL-1β maintains the redox balance by regulating glutaredoxin 1 expression during oral carcinogenesis. J Oral Pathol Med. 2016;46:332-39.
83.
Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol. 2002;169:469–75.PubMedCrossRef
84.
Jung YJ, Isaacs JS, Lee S, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. Faseb J. 2003;17:2115.PubMed
85.
Saha B, Arase A, Imam SS, et al. Overexpression of E-cadherin and β-catenin proteins in metastatic prostate cancer cells in bone. Prostate. 2008;68:78–84.PubMedCrossRef
86.
Chung ST, Geerts D, Roseman K, et al. Osteoprotegerin mediates tumor-promoting effects of interleukin-1beta in breast cancer cells. Mol Cancer. 2017;16:27.PubMedPubMedCentralCrossRef
87.
Baud'Huin M, Duplomb L, Teletchea S, et al. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev. 2013;24:401–9.PubMedCrossRef
88.
89.
Paquette B, Therriault H, Wagner JR. Role of interleukin-1β in radiation-enhancement of MDA-MB-231 breast cancer cell invasion. Radiat Res. 2013;180:292–8.PubMedCrossRef
90.
Han J, Bae SY, Oh SJ, et al. Zerumbone suppresses IL-1尾-induced cell migration and invasion by inhibiting IL-8 and MMP-3 expression in human triple-negative breast cancer cells. Chin J Rock Mech Eng. 2014;131:4862–3.
91.
Holen I, Lefley DV, Francis SE, et al. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016;7:75571–5584.
92.
Thomas S, Merchant S, Meade R et al. Abstract 2533: Interlukin-1 (IL-1) may induce prostate cancer (PCa) stem-like cells. 2016.
93.
Elomar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402.CrossRef
94.
Karin M, Cao Y, Greten FR, et al. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.PubMedCrossRef
95.
Huang F, Chan AO, Rashid A et al. Interleukin-1β increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. Oncology Letters. 2016;11(4):2919-2924.
96.
Economides AN, Carpenter LR, Rudge JS, Wong V, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47–52.PubMedCrossRef
97.
98.
99.
Nagasaki T, Hara M, Nakanishi H, et al. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction. Br J Cancer. 2014;110:469.PubMedCrossRef
100.
Rosejohn S, Scheller J, Elson G, et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80:227–36.CrossRef
101.
Kastritis E, Charidimou A, Varkaris A, et al. Targeted therapies in multiple myeloma. Target Oncol. 2009;4:23.PubMedCrossRef
102.
Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Curr Pharm Des. 2008;14:1217–24.PubMedCrossRef
103.
Duan Z, Feller AJ, Penson RT, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 1999;5:3445–53.PubMed
104.
Duan Z, Lamendola DE, Penson RT, et al. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine. 2002;17:234–42.PubMedCrossRef
105.
Pu YS, Hour TC, Chuang SE, et al. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate. 2004;60:120–9.PubMedCrossRef
106.
Wang Y, Niu XL, Qu Y, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010;295:110.PubMedCrossRef
107.
Zou M, Zhang X, Xu C. IL6-Induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells. Cell Oncol. 2016;39:47.CrossRef
108.
Peng D, Tanikawa T, Li W, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling. Cancer Res. 2016;76:3156.PubMedPubMedCentralCrossRef
109.
Ohara J, Paul WE. Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature. 1987;325:537–40.PubMedCrossRef
110.
Shi Y, Frost PJ, Hoang BQ, et al. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res. 2008;68:10215–22.PubMedPubMedCentralCrossRef
111.
Lauta VM. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine. 2001;16:79.PubMedCrossRef
112.
Songür N, Kuru B, Kalkan F, et al. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori. 2004;90:196–200.PubMed
113.
Altundag O, Altundag K, Gunduz E. Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J Clin Oncol. 2005;23:1044. author reply 1044-1045PubMedCrossRef
114.
Negrier S, Perol D, Menetriercaux C, et al. Interleukin-6, Interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of Interleukin-6—from the Groupe Français d'Immunothérapie. J Clin Oncol. 2004;22:2371–8.PubMedCrossRef
115.
Garcia-Tuñón I, Ricote M, Ruiz A, et al. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology. 2005;47:82–9.PubMedCrossRef
116.
Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103:642–6.PubMedCrossRef
117.
Belluco C, Nitti D, Frantz M, et al. Interleukin-6 blood level is associated with circulating Carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000;7:133–8.PubMedCrossRef
118.
Bellone S, Watts K, Cane’ S, et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 2005;98:92–8.
119.
Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22:1517.PubMedCrossRef
120.
Zakrzewska I, Poznański J. Changes of serum il-6 and CRP after chemotherapy in patients with ovarian carcinoma. Pol Merkur Lekarski. 2001;11:210–3.PubMed
121.
Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000;10:33–41.PubMedCrossRef
122.
Matsuoka Y, Nakayama H, Yoshida R, et al. TAMS and IL-6 contribute to resistance to radiotherapy in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2015;44:e261.CrossRef
123.
Culig Z, Steiner H, Bartsch G, et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95:497–505.PubMedCrossRef
124.
Hara M, Nagasaki T, Shiga K et al. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab. Surgery Today. 2016;7:483-489.
125.
Ando K, Takahashi F, Motojima S, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2013;31:69–72.CrossRef
126.
Wan S, Zhao E, Kryczek I, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human Hepatocellular carcinoma stem cells. Gastroenterology. 2014;147:1393–404.PubMedPubMedCentralCrossRef
127.
George DJ, Halabi S, Shepard TF, et al. The prognostic significance of plasma Interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005;11:1815–20.PubMedCrossRef
128.
He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155:384–96.PubMedPubMedCentralCrossRef
129.
130.
Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Investig. 2007;117:3988.PubMedPubMedCentralCrossRef
131.
Jono H, Shinriki S, Nakamura H, et al. Antitumor effect of humanized anti-interleukin. J Neurosurg. 2009;111:219–25.PubMedCrossRef
132.
Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2013;141:125–39.PubMedCrossRef
133.
Shinriki S, Jono H, Ota K, et al. Humanized anti-Interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral Squamous cell carcinoma. Clin Cancer Res. 2009;15:5426–34.PubMedCrossRef
134.
Shinriki S, Jono H, Ueda M, et al. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma †. J Pathol. 2011;225:142–50.PubMedCrossRef
135.
Rossi JF, Négrier S, James ND, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103:1154–62.PubMedPubMedCentralCrossRef
136.
Karkera J, Steiner H, Li W, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study † ‡ §. Prostate. 2011;71:1455–65.PubMedCrossRef
137.
Fulciniti M, Hideshima T, Vermot-Desroches C, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009;15:7144–52.PubMedPubMedCentralCrossRef
138.
Moreau P, Harousseau JL, Wijdenes J, et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol. 2000;109:661–4.PubMedCrossRef
139.
Rossi JF, Fegueux N, Lu ZY, et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant. 2005;36:771.PubMedPubMedCentralCrossRef
140.
Bayliss TJ, Smith JT, Schuster M, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011;11:1663–8.PubMedCrossRef
141.
142.
Chari A, Pri-Chen H, Jagannath S. Complete remission achieved with single agent CNTO 328, an anti–IL-6 monoclonal antibody, in relapsed and refractory myeloma. Clin Lymphoma Myeloma Leuk. 2013;13:333–7.PubMedCrossRef
143.
144.
Kassar RCJ, Chan AW, Lilly LB, Al Habeeb A, Rotstein C. Leflunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient. Transpl Infect Dis. 2017;19:e12702.
145.
146.
Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119:4614–8.PubMedPubMedCentralCrossRef
147.
Joshi BH, Leland P, Lababidi S, et al. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease. Cancer Med. 2014;3:1615–28.PubMedPubMedCentralCrossRef
148.
Prokopchuk O, Liu Y, Henne-Bruns D et al. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. British Journal of Cancer. 2005;92:921–28.
149.
Todaro M, Lombardo Y, Francipane MG, et al. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 2008;15:762.PubMedCrossRef
150.
Laporte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132:259–72.PubMedPubMedCentralCrossRef
151.
Willskarp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal. 2008;1:pe55.
152.
Obiri NI, Debinski W, Leonard WJ, et al. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem. 1995;270:8797–804.PubMedCrossRef
153.
Murata T, Puri RK. Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells. Cell Immunol. 1997;175:33–40.PubMedCrossRef
154.
Murata T, Husain SR, Mohri H, et al. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol. 1998;10:1103–10.PubMedCrossRef
155.
156.
Ostrand-Rosenberg S, Grusby MJ, Clements VK. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol. 2000;165:6015.PubMedCrossRef
157.
Ostrandrosenberg S, Sinha P, Clements V, et al. Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. Cancer Immunol Immunother. 2004;53:86.CrossRef
158.
Kacha AK, Fallarino F, Markiewicz MA, et al. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2001;165:6024–8.CrossRef
159.
Zhang WJ, Li BH, Yang XZ, et al. IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine. 2008;42:39–47.PubMedCrossRef
160.
Tepper RI, Levinson DA, Stanger BZ, et al. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell. 1990;62:457–67.PubMedCrossRef
161.
Hock H, Dorsch M, Kunzendorf U, et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci. 1993;90:2774–8.PubMedPubMedCentralCrossRef
162.
Gocheva V, Wang HW, Gadea BB, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24:241.PubMedPubMedCentralCrossRef
163.
Vasiljeva O, Papazoglou A, Krüger A, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006;66:5242.PubMedCrossRef
164.
Yan X, Li W, Pan L, et al. Lewis lung cancer cells promote SIGNR1(CD209b)-mediated macrophages polarization induced by IL-4 to facilitate immune evasion. J Cell Biochem. 2015;117:1158.PubMedCrossRef
165.
König A, Vilsmaier T, Rack B, et al. Determination of Interleukin-4, −5, −6, −8 and −13 in serum of patients with breast cancer before treatment and its correlation to circulating tumor cells. Anticancer Res. 2016;36:3123–30.PubMed
166.
Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002;4:65–9.PubMedPubMedCentralCrossRef
167.
Ginestier C, Min HH, Charafe-Jauffret E, et al. ALDH1 Is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.PubMedPubMedCentralCrossRef
168.
Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253–70.PubMedPubMedCentralCrossRef
169.
Charafejauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302–13.CrossRef
170.
Razmkhah M, Jaberipour M, Erfani N, et al. Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response? Cell Immunol. 2011;266:116.PubMedCrossRef
171.
Uygur B, Leikina E, Chernomordik L. Abstract 925: IL-4 / IL-13 mediated cell-to-cell fusion in prostate cancer progress. Cancer Research. 2016;76:925–925.
172.
Maeurer MJ, Martin DM, Castelli C, et al. Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1995;41:111–21.PubMedCrossRef
173.
Venmar KT, Carter KJ, Hwang DG, et al. IL-4 receptor ILR4α regulates metastatic colonization by mammary tumors through multiple signaling pathways. Cancer Res. 2014;74:4329–40.PubMedPubMedCentralCrossRef
174.
Denardo D, Baretto J, Coussens L. CD4+ T cells regulate macrophage phenotype and functionally contribute to mammary tumor progression. Cancer Res. 2008;68:4196.
175.
Iwashita J, Sato Y, Sugaya H, et al. mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol. 2003;81:275–82.PubMedCrossRef
176.
Todaro M, Alea MP, Stefano ABD, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of Interleukin-4. Cell Stem Cell. 2007;1:389.PubMedCrossRef
177.
178.
Rudolph J, Heine A, Quast T, et al. The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. Leukemia. 2016;30:2119–123.
179.
Siemasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 1996;61:635.PubMedCrossRef
180.
Friedman OR, Kirkland TA, Woodroofe CC, et al. Deciphering the cellular targets of bioactive compounds using a Chloroalkane capture tag. ACS Chem Biol. 2015;10:2316.CrossRef
181.
Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature reviews. Drug discovery. 2005;4:988-1004.
182.
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9.PubMedCrossRef
183.
Bhadresha R. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–66.CrossRef
184.
Gibeon D, Menzies-Gow AN. Targeting interleukins to treat severe asthma. Expert Rev Respir Med. 2012;6:423–39.PubMedCrossRef
185.
Maes T, Joos GF, Brusselle GG. Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol. 2012;47:261–70.PubMedCrossRef
186.
187.
Mcdermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133.PubMedCrossRef
188.
Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordina. J Clin Oncol. 2008;26:5748–54.PubMedPubMedCentralCrossRef
189.
Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 Peptide vaccine and Interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119–27.PubMedPubMedCentralCrossRef
190.
Radvanyi LG, Chantale B, Minying Z, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer. 2012;18:6758–70.CrossRef
191.
Liu KJ, Chao TY, Chang JY, et al. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. J Biomed Sci. 2016;23:64.PubMedPubMedCentralCrossRef
192.
Neri D, Weide B, Eigentler TK, et al. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: clinical and systemic immunological responses. Cancer Immunol Res. 2014;2:668–78.PubMedCrossRef
193.
Danielli R, Patuzzo R, Giacomo AMD, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015;64:999.PubMedCrossRef
194.
195.
Quintás-Cardama A, Manshouri T, Estrov Z, et al. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Investig New Drugs. 2011;29:818.CrossRef
196.
Enomoto A, Rho MC, Fukami A, et al. Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem Biophys Res Commun. 2004;323:1096–102.PubMedCrossRef
197.
Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol. 2011;7:1035–43.PubMedPubMedCentralCrossRef
198.
Teschner S, Burst V. Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy. 2017;2:637–50.CrossRef
199.
Blakely K, Gooderham M, Papp K. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature. Skin Therapy Lett. 2016;21:1.PubMed
200.
Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010;19:46–54.PubMedCrossRef
201.
Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999;160:1816–23.PubMedCrossRef
202.
Hart TK, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130:93–100.PubMedPubMedCentralCrossRef
Metadata
Title
Tumor-related interleukins: old validated targets for new anti-cancer drug development
Authors
Sarra Setrerrahmane
Hanmei Xu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2017
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-017-0721-9

Other articles of this Issue 1/2017

Molecular Cancer 1/2017 Go to the issue

Research

MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway

Research

BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma

Research

Phosphorylation by mTORC1 stablizes Skp2 and regulates its oncogenic function in gastric cancer

Review

Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention

Research

Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis

Review

Targeting acute myeloid leukemia stem cell signaling by natural products
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits